Rezolute Inc is expected to report a consensus EPS of -$0.18 on revenue of $1.12 million for the quarter ending September 30, 2026, with its current $4.01 stock price trading well below the average analyst target of $11.22.
Investors are primarily focused on the clinical progress of ersodetug (RZ358), specifically the upcoming topline data from the Phase 3 upLIFT study in tumor hyperinsulinism expected in mid-December 2026.
Recent updates confirmed the upLIFT trial is fully enrolled, following positive interim results that showed a high percentage of participants achieving responder criteria.
Analysts are also watching for management's commentary on the cash runway and the potential timeline for a Biologics License Application (BLA) submission for congenital hyperinsulinism.